Oncology
Latest news
915 articles · 20 / page
Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer
A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of
AI-Derived Sarcopenia Metrics Predict Survival Benefit from Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer
A deep learning analysis of the PanaMa trial reveals that the benefit of adding panitumumab to maintenance therapy for RAS wild-type mCRC is significantly higher in patients with a high muscle-bone ratio, suggesting a new AI-driven approach
Muscle-Bone Ratio: A New AI-Driven Biomarker for Anti-EGFR Response in Metastatic Colorectal Cancer
A deep learning-derived sarcopenia marker, the muscle-bone ratio (MBR), has been shown to predict the efficacy of anti-EGFR maintenance therapy in patients with RAS wild-type metastatic colorectal cancer, potentially identifying those who t
Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial
The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhance
More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer
Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while s
Beyond Detection: How ctDNA Dynamics Predict Treatment Success in Advanced Breast Cancer
The plasmaMATCH trial establishes ctDNA testing as a highly accurate tool for directing targeted therapies in advanced breast cancer. New data reveal that baseline ctDNA levels and early on-treatment dynamics serve as powerful prognostic ma
Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?
The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.
Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminati
Elacestrant Reinforces Its Role in the Real-World Management of ESR1-Mutated Metastatic Breast Cancer
This real-world study demonstrates that elacestrant provides a durable benefit for patients with ER+/HER2- ESR1-mutated metastatic breast cancer, maintaining efficacy across various treatment lines and in patients with visceral metastases o
Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial
A randomized clinical trial demonstrates that telehealth-delivered music therapy is noninferior to cognitive behavioral therapy for reducing anxiety in cancer survivors, providing durable, clinically meaningful improvements and a viable alt
Industrial Food Preservatives Linked to Increased Cancer Risk: Evidence from the NutriNet-Santé Prospective Cohort
A large-scale prospective study of over 100,000 participants identifies significant associations between specific food preservatives, including sorbates, nitrites, and nitrates, and an increased risk of overall, breast, and prostate cancers
2025 FDA Drug Approvals: A Critical Review of New Therapeutic Frontiers and Regulatory Shifts
A comprehensive analysis of the 46 novel drugs approved by the FDA in 2025, highlighting breakthroughs in oncology, chronic pain, and respiratory medicine, alongside significant regulatory changes and a preview of the 2026 pipeline.
Active Cancer Increases Both Ischemic and Bleeding Risks in Minor Stroke Patients on DAPT: Lessons from the READAPT Study
A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in
Precision Prognosis: Navigating Decision-Making in Head and Neck Cancer Through Individualized Counseling
This review analyzes the impact of individualized prognostic counseling on decisional conflict and regret in patients with head and neck squamous cell carcinoma, highlighting the efficacy of online prognostic tools in fostering shared decis
Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard
A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatmen
Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial
The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man
Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial
The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced o
Dual Checkpoint Inhibition: Tiragolumab and Atezolizumab Set New Survival Benchmarks in Advanced Esophageal Squamous Cell Carcinoma
The Phase 3 SKYSCRAPER-08 trial demonstrates that adding the anti-TIGIT tiragolumab and anti-PD-L1 atezolizumab to chemotherapy significantly extends overall survival and progression-free survival in patients with treatment-naive, unresecta
Molecular-Based Adjuvant Therapy Proves Safe and Effective in High-Intermediate Risk Endometrial Cancer: Results from the PORTEC-4a Trial
The PORTEC-4a trial confirms that molecular profiling safely guides adjuvant treatment in high-intermediate risk endometrial cancer, reducing overtreatment by 46% while maintaining non-inferiority in locoregional control compared to standar
Adjuvant Temozolomide for IDH-Mutated Anaplastic Astrocytoma: Final CATNON Results Confirm a Decade of Survival Benefit
The final analysis of the EORTC CATNON trial reveals that 12 cycles of adjuvant temozolomide significantly extend overall survival to 12.5 years in IDH-mutated anaplastic astrocytoma, whereas concurrent temozolomide provides no added clinic
Browse by specialty
Open language-specific specialty feeds and department pages.